Alcidion Reconfirms FY26 Guidance and Completes Acquisition
Key points
- FY26 revenue guidance reconfirmed over $50M
- EBITDA expected to exceed $5.0M
- Acquisition of Kyra flow products completed, adding 33 customers
Full summary
Alcidion Group Limited (ASX:ALC) has reconfirmed its FY26 guidance, expecting revenue to exceed $50M and EBITDA to exceed $5.0M. The company also completed the acquisition of Kyra flow products from Telstra Health, adding 33 customers. The acquisition is immediately earnings accretive and is expected to enhance Alcidion's position in the patient flow market.
Guidance
FY26 revenue expected over $50M, EBITDA over $5.0M, operating cashflow in-line with FY25
Outlook
Alcidion is well positioned for continued growth with long-term contracted revenue extending into the mid-2030s.
Summary generated by a large language model. Please interpret with care.